Evidence map›Paper›PMID 22928902›Full record

ReviewExpert review of gastroenterology & hepatology2012

Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.

Nathaniel S Rial, Jason A Zell, Alfred M Cohen, Eugene W Gerner

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of gastroenterology & hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Nathaniel S RialDepartment of Internal Medicine, The University of Arizona Medical Center, PO Box 245040, 1501 N Campbell Avenue, Tucson, AZ 85724, USA.
Jason A Zell
Alfred M Cohen
Eugene W Gerner
Cancer Prevention Pharmaceuticals (United States) · USBanner - University Medical Center Tucson · USUniversity of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026
$57.9M
SPORE in Gastrointestinal CancerP50CA095060 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2002 to 2012
$25.3M
RESISTANCE TO BILE ACID INDUCED APOPTOSISP01CA072008 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 1997 to 2005
$6.9M
Phase III Colon Cancer Prevention TrialR01CA088078 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI MEYSKENS, FRANK L. · 2002 to 2006
$4.2M
Prevention of APC-Dependent Intestinal CarcinogenesisR01CA123065 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2007 to 2011
$1.6M
POLYAMINES IN CELL GROWTH AND RESPONSES TO STRESSR01CA047396 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 1988 to 1992
–
PHASE II CLINICAL TRIAL OF DFMO &NSAID IN COLONN01CN075019 · CN · UNIVERSITY OF CALIFORNIA-IRVINE · PI MEYSKENS, FRANK L. · 1997 to 2006
–
POLYAMINE DEPLETION AND CHEMOPREVENTION OF COLON CANCERR01CA059024 · NCI · UNIVERSITY OF CALIFORNIA IRVINE · PI MEYSKENS, FRANK LOUIS · 1993 to 1996
–
NCI NIH HHS CA047396NCI NIH HHS CA059024NCI NIH HHS CA072008NCI NIH HHS CA088078NCI NIH HHS CA095060NCI NIH HHS CA123065NCI NIH HHS CN075019NCI NIH HHS N01 CN075019NCI NIH HHS P01 CA072008NCI NIH HHS P30 CA062203NCI NIH HHS P50 CA095060NCI NIH HHS R01 CA059024NCI NIH HHS R01 CA088078NCI NIH HHS R01 CA123065
6 · The paper itself

Abstract

To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors.

Indexed as

ChemopreventionGenetic Predisposition to DiseaseAdenomatous Polyposis ColiAntineoplastic AgentsClinical Trials as TopicColonoscopyColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisEflornithineHumansInflammatory Bowel DiseasesNeoplasm Recurrence, LocalSulindacAntineoplastic AgentsEflornithineSulindac

Identifiers

PMID22928902
PMCPMC3587976
OpenAlexW1985519924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.